Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT) - PubMed (original) (raw)
Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT)
Malinda Lin et al. J Clin Immunol. 2009 Mar.
Abstract
Background: Hematopoietic stem cell transplantation (HSCT) is the only cure for patients with severe combined immunodeficiency (SCID). The purpose of this study was to evaluate long-term neurodevelopment of patients with SCID following myeloablative chemotherapy and HSCT.
Materials and methods: Sixteen pediatric patients diagnosed with SCID were tested using the Bayley Scales of Infant Development and the validated Vineland Adaptive Behavior Scales (VABS) pre- and 1-year post-HSCT. Three years post-HSCT, there were 11 patients available for testing and four patients available 5 years post-HSCT. Patients greater than 3 years of age were administered the Wechsler Preschool and Primary Scale of Intelligence. Both raw scores and scaled scores were analyzed.
Results: There was a significant decrease 1 year post-HSCT in the Bayley Mental Developmental Index (MDI) [92.5 (pre) vs. 70.81 (1 year post), p < 0.0001] and the VABS [99.73 (pre) vs. 79.87 (1 year post), p = <0.0001]. There was a significant decrease over time in the MDI [95.00 (pre) vs. 72.64 (1 year post) vs. 71.82 (3 years post), p < 0.0001], but no significant change between 1 and 3 years post-HSCT. There was no change in the Bayley Psychomotor Development Scale (PDI) [82.4 (pre) vs. 84.8 (1 year post), p = 0.68]. The PDI scores decreased over time [86.29 (pre) vs. 86 (1 year post) vs. 74.14 (3 years post), p = 0.045]. Although there was a decrease in scaled scores, there was not a loss of skills. Analysis of raw scores showed that there was an increase in the raw test scores, which indicated that these children acquired developmental skills, but at a slower rate than normal infants and toddlers. Younger children had a more significant decrease in adaptive scores compared with older children.
Conclusions: These findings may reflect the effects of the isolation and prolonged hospitalization that characterizes the immediate post-transplant period. Patients miss out on social interactions and learning opportunities that normally occur at their respective stages of development. These restrictions keep patients from acquiring developmentally appropriate cognitive skills as well as gross and fine motor developmental milestones. Longitudinal follow-up will be important to quantify acquisition of skills.
Figures
Fig. 1
A schematic diagram of the patients available for testing at different time points
Fig. 2
Mental development scores, psychomotor development scores, and adaptive behavior scores of SCID patients pre- and 1 year post-HSCT
Fig. 3
Mental development scores and psychomotor development scores of SCID patients pre-, 1 year, and 3 years HSCT
Fig. 4
a Raw scores of mental development pre-, 1 year, and 3 years post-HSCT. b Raw scores of psychomotor development pre-, 1 year, and 3 years post-HSCT
Similar articles
- Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation.
Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. Bjoraker KJ, et al. J Dev Behav Pediatr. 2006 Aug;27(4):290-6. doi: 10.1097/00004703-200608000-00002. J Dev Behav Pediatr. 2006. PMID: 16906003 - Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies.
Shah AJ, Epport K, Azen C, Killen R, Wilson K, De Clerck D, Crooks G, Kapoor N, Kohn DB, Parkman R, Weinberg KI. Shah AJ, et al. J Pediatr Hematol Oncol. 2008 Jun;30(6):411-8. doi: 10.1097/MPH.0b013e318168e750. J Pediatr Hematol Oncol. 2008. PMID: 18525456 - Hematopoietic stem cell transplantation for severe combined immune deficiency.
Weinberg KI, Kapoor N, Shah AJ, Crooks GM, Kohn DB, Parkman R. Weinberg KI, et al. Curr Allergy Asthma Rep. 2001 Sep;1(5):416-20. doi: 10.1007/s11882-001-0026-2. Curr Allergy Asthma Rep. 2001. PMID: 11892067 Review. - Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.
Cowan MJ, Neven B, Cavazanna-Calvo M, Fischer A, Puck J. Cowan MJ, et al. Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):73-5. doi: 10.1016/j.bbmt.2007.10.017. Biol Blood Marrow Transplant. 2008. PMID: 18162224 Review.
Cited by
- Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force.
Schofield HT, Fabrizio VA, Braniecki S, Pelletier W, Eissa H, Murphy B, Chewning J, Barton KD, Embry LM, Levine JE, Schultz KR, Page KM. Schofield HT, et al. Transplant Cell Ther. 2022 Oct;28(10):625-636. doi: 10.1016/j.jtct.2022.06.027. Epub 2022 Jul 21. Transplant Cell Ther. 2022. PMID: 35870778 Free PMC article. No abstract available. - Survey of Infection Control Precautions for Patients with Severe Combined Immune Deficiency.
Dergousoff BA, Vayalumkal JV, Wright NAM. Dergousoff BA, et al. J Clin Immunol. 2019 Nov;39(8):753-761. doi: 10.1007/s10875-019-00671-y. Epub 2019 Aug 20. J Clin Immunol. 2019. PMID: 31432442 - Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT.
Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Buchbinder D, et al. Bone Marrow Transplant. 2018 May;53(5):535-555. doi: 10.1038/s41409-017-0055-7. Epub 2018 Jan 17. Bone Marrow Transplant. 2018. PMID: 29343837 Free PMC article. Review. - Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening.
Dvorak CC, Puck JM, Wahlstrom JT, Dorsey M, Melton A, Cowan MJ. Dvorak CC, et al. Blood Adv. 2017 Sep 5;1(20):1694-1698. doi: 10.1182/bloodadvances.2017010835. eCollection 2017 Sep 12. Blood Adv. 2017. PMID: 29296816 Free PMC article. No abstract available. - Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.
Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Kelly DL, et al. Biol Blood Marrow Transplant. 2018 Feb;24(2):228-241. doi: 10.1016/j.bbmt.2017.09.004. Epub 2017 Sep 20. Biol Blood Marrow Transplant. 2018. PMID: 28939455 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources